Tel-Aviv University Future Technology Development L.P.
Records under this name other than patents Tel-Aviv University Future Technology Development L.P. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Tel-Aviv University Future Technology Development L.P.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,629,824 | Indole Derivatives and Process for Their Preparation Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 9,630,989 | Dipeptide Analogs for Treating Conditions Associated with Amyloid Fibril Formation Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 8,178,129 | Formulations of water insoluble or poorly water soluble drugs in lipidated glycosaminoglycan particles and their use for diagnostic and therapy Lapsed on the fee record Ended May 15, 2024 · USPTO record | Lapsed on the fee record | Ended May 15, 2024 | USPTO record |
| US 8,563,273 | Method of screening for compounds that disaggregate amyloid aggregates Term ended Term ended Apr 4, 2024 · USPTO record | Term ended | Term ended Apr 4, 2024 | USPTO record |
| US 7,446,092 | Glycogen Synthase KINASE-3 Inhibitors Term ended Term ended Feb 28, 2024 · High confidence | Term ended | Term ended Feb 28, 2024 | High confidence |
| US 7,544,374 | Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy Term ended Term ended Feb 27, 2024 · USPTO record | Term ended | Term ended Feb 27, 2024 | USPTO record |
| US 9,259,474 | Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy Lapsed on the fee record Ended Feb 16, 2024 · USPTO record | Lapsed on the fee record | Ended Feb 16, 2024 | USPTO record |
| US 8,697,634 | Peptides and methods using same for diagnosis and treatment of amyloid-associated disease Term ended Term ended Nov 23, 2023 · USPTO record | Term ended | Term ended Nov 23, 2023 | USPTO record |
| US 7,907,998 | Bio-impedance apparatus and method Lapsed on the fee record Ended Mar 15, 2023 · USPTO record | Lapsed on the fee record | Ended Mar 15, 2023 | USPTO record |
| US 7,781,396 | Peptides directed for diagnosis and treatment of amyloid-associated disease Term ended Term ended Jan 16, 2023 · USPTO record | Term ended | Term ended Jan 16, 2023 | USPTO record |